Abstract
The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.
| Original language | English |
|---|---|
| Title of host publication | Methods in Molecular Biology |
| Publisher | Humana Press Inc. |
| Pages | 97-105 |
| Number of pages | 9 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Volume | 1692 |
| ISSN (Print) | 1064-3745 |
Fingerprint
Keywords
- Heterogeneity
- Immunosuppressed mice
- Patient-derived xenografts
- Predictive model
- Stroma
- Transplantation assay
- Tumorigenicity
ASJC Scopus subject areas
- Molecular Biology
- Genetics
Cite this
Xenograft as in vivo experimental model. / Porru, Manuela; Pompili, Luca; Caruso, Carla; Leonetti, Carlo.
Methods in Molecular Biology. Humana Press Inc., 2018. p. 97-105 (Methods in Molecular Biology; Vol. 1692).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Xenograft as in vivo experimental model
AU - Porru, Manuela
AU - Pompili, Luca
AU - Caruso, Carla
AU - Leonetti, Carlo
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.
AB - The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.
KW - Heterogeneity
KW - Immunosuppressed mice
KW - Patient-derived xenografts
KW - Predictive model
KW - Stroma
KW - Transplantation assay
KW - Tumorigenicity
UR - http://www.scopus.com/inward/record.url?scp=85030778022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030778022&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-7401-6_9
DO - 10.1007/978-1-4939-7401-6_9
M3 - Chapter
C2 - 28986890
AN - SCOPUS:85030778022
T3 - Methods in Molecular Biology
SP - 97
EP - 105
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -